Evaxion Biotech AS
NASDAQ: EVAX · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-30
Evaxion Biotech AS (EVAX) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for EVAX.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
EVAX historical valuation range
Where current P/E sits in EVAX's own 5Y range.
EVAX intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
EVAX valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 4.46x
Is EVAX overvalued in 2026?
Evaxion Biotech AS (EVAX) currently trades at $4.41 per share with a market capitalization of $33,611,100.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 21/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
EVAX currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 4.5x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates EVAX's intrinsic value at $3.87 per share, against the current market price of $4.41. This implies a margin of safety of +14.47%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: EVAX appears richly valued on our framework, with a Smart Value Score of 21/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is EVAX overvalued in 2026?
Based on a Smart Value Score of 21/100, EVAX appears overvalued. Current price exceeds what fundamentals currently justify.
What is EVAX's fair value?
Our DCF model estimates EVAX's intrinsic value at $3.87 per share, versus the current price of $4.41. This produces a margin of safety of +14.47%.
What P/E ratio does EVAX trade at?
EVAX does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is EVAX a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 21/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does EVAX's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on EVAX.
What is EVAX's Smart Value Score?
EVAX's Smart Value Score is 21/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.